



30th Annual Cancer Progress Conference May 7-8, 2019 Convене, 32 Old Slip, NYC

May 7, 2019

7:00 – 8:00am

Registration and Continental Breakfast

8:00 – 8:15am

Opening Remarks

Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

8:15 – 9:15am

Keynote:

Realizing the Full Potential of CRISPR for Cancer Therapies and Other Precision Medicines

Speaker: Rachel Haurwitz, PhD, Chief Executive Officer and Founder, Caribou Biosciences, Inc.

9:15 – 10:30am

Has the Time Come for Chemo- & Immuno-Prevention: Nixing the Nabobs of Negativity

Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

Panelists:

- John Letterio, MD, Division Chief, Pediatric Hematology and Oncology, UH Cleveland Medical Center Division Chief, Pediatric Hematology and Oncology, UH Rainbow Babies and Children's Hospital Professor, Pediatrics, CWRU School of Medicine Interim Director, UH Seidman Cancer Center
- Nicholas Sarlis, MD, PhD, FACP, FAPCR, Chief Medical Officer & Executive VP, Sellas Life Sciences Group, Inc.
- Michael B. Sporn, MD, Professor of Pharmacology and Medicine/Molecular and Systems Biology/Active Emeritus, Dartmouth Medical School

10:30 – 11:00am

Networking Break

11:00 – 12:15pm

Novel Ways to Target and Develop Therapies for Cancer Metastases: Stop Spreading the New

Moderator: Joel S. Sandler, PhD, Associate Principal, Cello Health BioConsulting, previously Defined Health

Panelists:

- Yibin Kang, PhD, Warner-Lambert/Parke-Davis Professor of Molecular Biology, Princeton University
- Llew Kerner, MD, PhD, CEO, Epistat
- Chand Khanna, DVM, PhD, DACVP, Director, Vuja De Sciences Chief Science Officer, Ethos Veterinary Health, President, Ethos Discovery Vuja De
- Jackson Streeter MD, Senior VP Corporate Development and Strategy, Quanterix
- Maurice Zauderer, PhD, President & Chief Executive Officer, Vaccinex, Inc.



12:15 – 1:30pm

Networking Luncheon & Keynote:

Forward Thinking on the Future Oncology Biotech Supply Channel and Realities for Value Based Contracting

Speaker: Burt Zweigenhaft, Managing Partner, Upstream Partners Inc.

1:30 – 2:45pm

Basket Trials Revisited: Faster, Better, Smarter Trials/Precision Medicine: Insights and Remaining Challenges, Perspectives from Academia, Pharma and Biotech

Moderator: Brian Leyland Jones, MBBS, PhD, VP, Avera Cancer Institute Center for Precision Oncology & Dept. of Molecular & Experimental Medicine, Avera Cancer Institute

Panelists:

- Peter J. O'Dwyer, MD, Group Co-Chair, ECOG-ACRIN Cancer Research Group; Abramson Cancer Center, University of Pennsylvania
- Richard L. Schilsky, MD, FACP, FSCT, FASCO, Senior Vice President and Chief Medical Officer, American Society of Clinical Oncology
- Gisela Schwab, MD, President, Product Development and Medical Affairs and Chief Medical Officer, Exelixis, Inc.
- Apostolia-Maria Tsimberidou, MD, PhD, Professor, Department of Investigational Cancer Therapeutics M. D. Anderson Cancer Center, University of Texas

2:45 – 3:15pm

Networking Break

3:15 – 4:30pm

IO Session I: Combination Failures & Futures: Much Ado About What?

Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

Panelists

- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- Axel Hoos, MD, PhD, SVP Therapeutic Area Head R&D, Head Immuno-Oncology, GlaxoSmithKline
- Ramy Ibrahim, MD, Chief Medical Officer, Parker Institute For Cancer Immunotherapy
- Vanessa Lucey, PhD, MBA, Director, Cancer Research Institute
- Robert Stein, MD, PhD, Senior R&D Advisor, Agenus
- Mai-Britt Zocca, PhD, Chief Executive Officer, IO Biotech

5:00 – 7:00pm

Cancer Progress 2019 Reception



May 8, 2019

7:00 – 8:00am

Registration and Continental Breakfast

8:00 – 8:15am

Opening Remarks: Review of Day 1

Joel S. Sandler, PhD, Associate Principal, Cello Health BioConsulting, previously Defined Health

8:15 – 9:30am

Payer/Access Panel

Moderator: Ed Saltzman, Executive Chairman, Cello Health BioConsulting, previously Defined Health

Panelists

- Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Roger Longman, Chief Executive Officer, Real Endpoints
- Burt Zweigenhaft, Managing Partner, Upstream Partners Inc.

9:30 – 10:45am

IO Session II: IO Targets and Platforms - Target Versus Modality - What Are the Keys to the Kingdom?

Moderator: Joel S. Sandler, PhD, Associate Principal, Cello Health BioConsulting, previously Defined Health

Panelists:

- Frank Borriello, Founder & Chief Executive Officer, Alloplex Biotherapeutics
- Ramy Ibrahim, MD, Chief Medical Officer, Parker Institute For Cancer Immunotherapy
- Louis Matis, MD, SVP and Chief Development Officer, Pieris Pharmaceuticals
- Eric Poma, MD, PhD, CEO/CSO, Molecular Templates, Inc.
- Dan Shoemaker, PhD, CSO, Fate Therapeutics

10:45 – 11:15am

Networking Break

11:15am – 12:30pm

Gynecological & Breast Cancers, Much Progress, Much to Do: How Novel Therapies from PARPs to Immunotherapies Are Transforming Care

Moderator: James T. Lee, PhD, Associate Principal, Oncology Lead, Cello Health BioConsulting, previously Defined Health

Panelists

- Brian Leyland Jones, MBBS, PhD, VP, Avera Cancer Institute Center for Precision Onc & Dept of Molecular & Experimental Medicine, Avera Cancer Institute
- Martin Lehr, CEO, Context Therapeutics
- Patrick Mahaffy, President & CEO, Clovis Oncology
- Dmitry Zamarin, MD, PhD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center



12:30 – 1:45pm

Biotech Deal-Making in the Face of IO Frenzy or Fatigue: Same Old or Different New?

Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

Panelists:

- Jean Chang, Vice President, Corporate Development & Oncology Project Lead, Dynavax
- Jane Dancer, Chief Business Officer, F-star Biotech
- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- Helen Tayton-Martin, PhD, MBA, Chief Business Officer, Adaptimmune
- Jill O'Donnell-Tormey, PhD, Chief Executive Officer & Director, Scientific Affairs, Cancer Research Institute
- Mark Simon, Managing Director, Torrey

1:45 – 3:00pm

Networking Luncheon & Keynote:

The Biden Cancer Initiative: Helping to build the cancer research and care system you think we already have

Speaker: Gregory C. Simon, President, Biden Cancer Initiative

3:00– 4:15pm

Insights from Heme Malignancies: Making Breakthrough Conventional and Unconventional Therapies Accessible Beyond Niche Blood Cancer Patients

Moderator: Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

Panelists:

- Chris Bowden, MD, CMO, Agios Pharmaceuticals
- Lee Greenberger, VP and Chief Scientific Officer, The Leukemia & Lymphoma Society
- Dan Shoemaker, PhD, CSO, Fate Therapeutics
- Vatnak Vat-Ho, Vice President, Business Development, Affimed

4:15 – 5:30pm

Oncology Innovation Powered by Investments and Competition from China

Moderator: James T. Lee, PhD, Associate Principal, Oncology Lead, Cello Health BioConsulting, previously Defined Health

Panelists:

- Iris Luo, MS, MBA, Head of Business Development, North America, CStone Pharmaceuticals
- Ian Somaiya, CFO, TCR² Therapeutics
- Ian Woo, President & CFO, Everest Medicines
- Jack Wu, PhD, Head of Business Development (USA), Adlai Nortye

5:30pm

Cancer Progress 2019 Conference Concludes